News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
kalkine.ca Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
An insider at Cybin Inc. recently purchased shares valued at $1,347,050, as detailed in a recent SEC filing. This transaction follows several other insider share purchases at Cybin throughout September, ranging from $1.04 million to $1.25 million. Cybin Inc. is a clinical-stage biopharmaceutical company โฆ
Cybin (NASDAQ:HELP) shares traded 9.7% higher on Monday, despite a 61% decrease in trading volume compared to its average. The company, which is focused on developing psychedelic-based therapeutics for mental health, has a market capitalization of $1.07 billion but remains unprofitable with a negative โฆ
Cybin Inc.'s stock (operating as Helus Pharma) dropped 10.96% on September 18, 2026, due to profit-taking and increased market volatility, despite no specific adverse company announcement. The company's valuation is highly sensitive to the success of its clinical development pipeline, particularly its lead program โฆ
Cybin Inc. (HELP) stock recently dipped by 11.13% following a volatile reversal move, driven by bearish sentiment over psychedelic sector regulation and funding risks. Despite significant operating losses and no revenue, the company maintains a strong balance sheet with substantial cash reserves, offering a โฆ
Cybin is expecting fourth-quarter Phase 3 data for its depression drug HLP003, a deuterated psilocin analog being developed as an adjunctive treatment for major depressive disorder. The PARADIGM program includes two pivotal studies and an extension study, building on encouraging Phase 2 results that โฆ
Cybin Inc. (NASDAQ:HELP) has received a consensus "Buy" recommendation from five brokerages, with an average 12-month price target of $48.60 despite a recent quarterly earnings miss. The stock opened at $13.61, near its 52-week high, and has seen significant insider buying totaling $7.0 million โฆ
Cybin Inc. (CN:HELP), operating as Helus Pharma, experienced a 5.91% stock decline amidst clinical-stage risk and investor expectations surrounding its lead program, HLP003, for major depressive disorder. The company has completed enrollment for its pivotal Phase 3 APPROACH study, with topline data anticipated in โฆ
Cybin insider Paul Glavine recently purchased 100,000 shares of the company's stock for $1.178 million at an average price of $11.78, increasing his total stake to 4.17 million shares. This follows a previous purchase of 90,000 shares worth $1.04 million in late August. The โฆ
Cybin Inc. (CN:HELP) saw its shares rise 10.56% on September 9, 2026, driven by increasing investor confidence in its psychedelic therapeutics pipeline for mental health treatments. The company's business model is centered on research and clinical development of novel psychedelic compounds, with growth prospects โฆ
Eric H. L. So, co-founder and executive chair of Cybin Inc., has disclosed a 5.8% stake in the company through recent share purchases and restricted stock unit awards. This investment signals personal commitment and compensation-linked equity, aligning his interests with Cybinโs progress in psychedelic-based โฆ
CYBIN (NASDAQ: HELP) CEO Michael Halstead will participate in a fireside chat at the Cantor Global Healthcare Conference from September 9-11, 2026. The event, taking place in New York City, will include a live webcast and replay, offering investors insights into CYBIN's progress with โฆ
Cybin Inc. (CN:HELP) shares dropped 3.76% on August 31, 2026, extending a period of weakness driven by clinical-stage risks, increasing losses, and investor reassessment. As a clinical-stage biotechnology company developing psychedelic-derived treatments for mental health, its valuation is heavily dependent on successful clinical trials, โฆ
Cybin Inc. shares dropped 4.12% on August 31, 2026, amid profit-taking after a significant August rally and continuing investor concerns over cash burn and upcoming clinical data. The company, now operating commercially as Helus Pharma, is nearing crucial Phase 3 topline results for HLP003 โฆ
Cybin Inc. (NASDAQ:HELP) shares dropped 4.5% during mid-day trading on Monday, with trading volume significantly below average. Despite this, analyst sentiment remains positive, with a consensus "Buy" rating and an average price target of $48.60. The company recently reported a quarterly loss of $0.91 โฆ
Cybin Inc. (CN:HELP), a clinical-stage biopharmaceutical company focused on psychedelic-based therapeutics for mental health, experienced a 7.51% stock decline due to investor caution in the biotechnology sector. The company's performance is highly sensitive to clinical trial progress, regulatory approvals, and funding given its pre-commercialization โฆ
Wall Street Zen has upgraded Cybin's stock rating from "strong sell" to "sell," while the broader analyst consensus for Cybin remains "Buy" with an average price target of $48.60. Despite this upgrade, Cybin shares fell 8.0% to $12.18, and the company reported a quarterly โฆ
Cybin Inc. (CN:HELP) saw its stock fall by 3.42% on August 27, 2026, reflecting renewed investor caution towards clinical-stage biotechnology companies. The decline is attributed to the inherent risks of clinical development, the company's reliance on external financing as it lacks commercial revenue, and โฆ
Cybin Inc. (Helus Pharma) saw its stock decline by 3.42% on August 27, 2026, indicating increased volatility and profit-taking amidst high expectations for its clinical pipeline. The company, a clinical-stage pharmaceutical firm developing novel serotonergic agonists for psychiatric disorders, faces significant clinical execution, funding, โฆ
Cybin Inc. (CN:HELP), operating as Helus Pharma, has seen renewed investor interest due to advancements in its psychedelic medicine pipeline, particularly the Phase 3 APPROACH study for HLP003 targeting major depressive disorder. The company's stock rose by 3.85% on August 24, 2026, driven by โฆ
Cybin Inc. (CN:HELP), operating as Helus Pharma, saw its shares rise by 5.23% due to optimism surrounding its lead depression candidate, HLP003, which is in pivotal Phase 3 development. The company has completed enrollment for the APPROACH study, with topline data expected later this โฆ
HC Wainwright has revised its earnings per share (EPS) forecasts for Cybin (NASDAQ:HELP), narrowing the expected Q2 2027 loss to $0.67 per share and projecting profitability by FY2030 at $0.62 EPS, increasing to $3.78 by FY2031. Despite continued near-term losses, analyst sentiment remains bullish, โฆ
Cybin Inc. (NASDAQ:HELP) has received an average "Buy" rating from all five analysts covering the stock, with an average 12-month price target of $48.60. Recent analyst actions include TD Cowen raising its price target to $62 and Wells Fargo initiating coverage with a $16 โฆ
Helus Pharma (HELP) stock surged 6% after TD Cowen significantly increased its price target from $8 to $62, citing clearer timelines for late-stage data, a new CEO, and positive trends in the psychedelic neuropsychiatry sector. The company's lead drug, HLP003, is in late-stage trials โฆ
Cybin's (NASDAQ:HELP) stock price increased by 6.1% after TD Cowen raised its price target from $8 to $62, maintaining a Buy rating. The company has a consensus "Buy" rating and an average price target of $48.60 from five analysts, with Wells Fargo initiating coverage โฆ
Analysts have increased their fair value estimate for Cybin (Helus Pharma) to $41.62 per share, up 11% from $37.57, due to higher projected revenue growth and stronger profit margins, driven by confidence in regulatory trends and positive sector research. The company, operating under Cybin โฆ
Cybin Inc. (trading as Helus Pharma, stock symbol HELP) is calling for a virtual shareholder meeting on September 22, 2026, where key proposals include approving financial statements, appointing auditors, setting the board size, and changing the company's name to "Helus Pharma Inc." The company's โฆ
Cybin Inc. (HELP) has filed a Form D to report an exempt equity compensation offering involving 425,000 performance share units (PSUs). These PSUs will vest annually through August 3, 2029, contingent on specific conditions, and are intended for executives, directors, or other related persons. โฆ
Cybin Inc. (NYSE: HELP) has filed a Form D for an exempt offering of 1.18 million restricted share units (RSUs) under Rule 506(b) of Regulation D. These RSUs will vest annually through August 20, 2029, with the first sale date noted as August 3, โฆ
Cybin (NASDAQ:HELP) shares recently hit a new 52-week high of $12.05, trading significantly above its moving averages, despite reporting a quarterly loss of $0.91 per share, missing analyst estimates. Wells Fargo initiated coverage with an "overweight" rating and a $16 price target, contributing to โฆ
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States